iBASKET Modules

iBASKET (Part B). Therapeutic portion

Module 1 – Immunogenetics

Immune-checkpoint blockade in genomically selected populations

  • Module leader: IGR and VHIO
  • Pharma partner: Roche

The current protocol contains the Module 1 of iBASKET with the following arms:

  • Arm 1A: BRCA1 or BRCA2 mutations
  • Arm 1B: MLH1, MSH2, MSH6, PMS2 mutations
  • Arm 1C: tumours with POLE mutation, POLD1 mutation
  • Arm 1D: hypermutated tumours
  • Arm 1E: tumours with other mutations in DNA-repair genes.
  • Arm 1F: tumours with amplified PDL1

Module 2 – FGFR

Futibatinib in subjects with FGFR-aberrant solid tumours

  • Module leader: VHIO
  • Pharma partner: Taiho Oncology, Inc

The current protocol contains the Module 2 of iBASKET with the following arms:

  • Arm 2A: Known pathogenic FGFR1-3 mutations.
  • Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.
  • Arm 2C: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio > 6) WITH high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).
  • Arm 2D: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio >6) WITHOUT high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).